Human cytomegalovirus retinitis: Pathogenicity, immune evasion and persistence

Trends in Microbiology

Volumn 11, Issue 4, 2003, Pages 171-178

  Scholz, Martin ^a   Doerr, Hans Wilhelm ^a   Cinatl, Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

CELLULAR IMMUNITY; DEREGULATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LATENT PERIOD; NONHUMAN; PERSISTENT VIRUS INFECTION; PIGMENT CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REGULATORY MECHANISM; RETINITIS; REVIEW; SIGNAL TRANSDUCTION; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS REPLICATION;

CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5;

EID: 0037386571     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(03)00066-0     Document Type: Review

References (69)

1. Egbert P.R., et al. Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann. Intern. Med. 93:1980;664-670.
2. Pepose J.S., et al. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology. 92:1985;472-484.
3. Jabs D.A., et al. Characteristic of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am. J. Ophthamol. 133:2002;48-61.
4. Lin D.Y., et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV-infected patients. Retina. 22:2002;268-277.
5. Schuman J.S., et al. Acquired immunodeficiency syndrome (AIDS). Surv. Ophthalmol. 31:1987;384-410.
6. Fowler K.B., et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:1992;663-667.
7. Crippa F., et al. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin. Infect. Dis. 32:2001;214-219.
8. Song M.-K., et al. Paradoxical activity of CMV retinitis in patients receiving highly active antiretroviral therapy. Retina. 22:2002;262-267.
9. Jabs D.A., et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am. J. Ophthalmol. 135:2003;26-34.
10. Gümbel H., et al. CMV retinitis: clinical experience with the metal chelator desferroxamine. Scholz M., et al. CMV-Related Immunopathology, Monographs in Virology. Vol. 21:1998;173-179 Karger, Basel.
11. Medawar P.B. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29:1948;58-69.
12. Barker C.F., Billingham R.E. Immunologically privileged sites. Adv. Immunol. 25:1977;1-54.
13. Streilein J.W., et al. Ocular immune privilege and the impact of intraocular inflammation. DNA Cell Biol. 21:2002;453-459.
14. Gabrielian K.R., et al. Effect of TGF-β on interferon-γ-induced HLA-DR expression in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 35:1994;4253-4259.
15. Jorgensen A., et al. Human retinal pigment epithelial cell-induced apoptosis in activated T cells. Invest. Ophthalmol. Vis. Sci. 39:1998;1590-1599.
16. Zhang X., Bok D. Transplantation of retinal pigment epithelial cells and immune response in the subretinal space. Invest. Ophthalmol. Vis. Sci. 39:1998;1021-1027.
17. Rao N.A., et al. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans. Am. Ophthalmol. Soc. 96:1998;111-123.
18. Pecorella I., et al. Postmortem histological survey of the ocular lesions in a British population of AIDS patients. Br. J. Ophthalmol. 84:2000;1275-1281.
19. Palestine A.G., et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 91:1984;1092-1099.
20. Jacobson M.A., et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 349:1997;1443-1445.
21. Karavellas M.P., et al. Immune recovery vitritis and uveitis in AIDS. Retina. 21:2001;1-9.
22. Kercher L., Mitchell B.M. Persisting murine cytomegalovirus can reactivate and has unique transcriptional activity in ocular tissue. J. Virol. 76:2002;9165-9175.
23. van den Pol A.N. Enhanced cytomegalovirus infection of developing brain independent of the adaptive immune system. J. Virol. 76:2002;8842-8854.
24. Taylor-Wiedeman J., et al. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72:1991;2059-2064.
25. Soederberg-Naucler C., et al. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J. Virol. 75:2001;7543-7554.
26. Soederberg-Naucler C., et al. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 91:1997;119-126.
27. Halary F., et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell transinfection. Immunity. 17:2002;653-664.
28. Jiang H.R., et al. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest. Ophthamol. Vis. Sci. 40:1999;3177-3185.
29. Murphy J.C., et al. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21:2002;1112-1120.
30. Cinatl J. Jr, et al. Human cytomegalovirus circumvents NF-κB dependence in retinal pigment epithelial cells. J. Immunol. 167:2001;1900-1908.
31. Prösch S., et al. CCAAT/enhancer-binding proteins alpha and beta negatively influence the capacity of tumor necrosis factor alpha to upregulate the human cytomegalovirus IE1/2 enhancer/promoter by nuclear factor kappaB during monocyte differentiation. J. Biol. Chem. 276:2001;40712-40720.
32. Cortes-Canteli M., et al. CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J. Biol. Chem. 277:2002;5460-5467.
33. Detrick B., et al. Cytomegalovirus replication in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 37:1996;814-825.
34. Fish K.N., et al. Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J. Virol. 69:1995;3737-3743.
35. Scholz M., et al. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res. 49:2001;129-145.
36. Speir E., et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ. Res. 83:1998;210-216.
37. Zhu H., et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3932-3937.
38. Mondino B.J., et al. Inflammatory mediators in the vitreous humor of AIDS patients with retinitis. Invest. Ophthalmol. Vis. Sci. 31:1990;798-804.
39. Bodaghi B., et al. Role of IFN-γ-induced indoleamine 2,3 dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162:1999;957-964.
40. Wang X.C., et al. Suppression of NF-κB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest. Ophthalmol. Vis. Sci. 40:1999;477-486.
41. Scholz M., et al. Cytomegalovirus- and interferon-related effects on human endothelial cells. Cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-gamma. Hum. Immunol. 35:1992;230-238.
42. Cinatl J. Jr, et al. Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced upregulation of Fas ligand independent of neutrophil apoptosis. J. Immunol. 165:2000;4405-4413.
43. Chiou S.H., et al. Upregulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: a novel mechanism in cytomegalovirus-induced apoptosis in human retina. J. Immunol. 167:2001;4098-4103.
44. Greenstein S., et al. Fas activation reduces neutrophil adhesion to endothelial cells. J. Leukoc. Biol. 68:2000;715-722.
45. Raftery M.J., et al. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity. 15:2001;997-1009.
46. Zhang H.G., et al. Antigen-presenting cells expressing Fas ligand downmodulate chronic inflammatory disease in Fas ligand-deficient mice. J. Clin. Invest. 105:2000;813-821.
47. Hueber A., et al. Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 240:2002;551-556.
48. Esser P., et al. CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 213:1995;1026-1034.
49. Sedger L.M., et al. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163:1999;920-926.
50. Sträter J., et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology. 122:2002;659-666.
51. Cinatl J. Jr, et al. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res. 58:1998;367-372.
52. Yu Y., Alwine J.C. Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3′-OH kinase pathway and the cellular kinase Akt. J. Virol. 76:2002;3731-3738.
53. Allart S., et al. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of δN-p73α J. Biol. Chem. 277:2002;29063-29068.
54. Skaletskaya A., et al. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7829-7834.
55. Goldmacher V.S., et al. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12536-12541.
56. Chiou S.H., et al. Apoptosis of human retina and retinal pigment cells induced by human cytomegalovirus infection. Ophthalmic Res. 34:2002;77-82.
57. Jiang S., et al. Fas mediates apoptosis and oxidant-induced cell death in cultured hRPE cell. Invest. Ophthalmol. Vis. Sci. 41:2000;645-655.
58. Zhang M., Atherton S.S. Apoptosis in the retina during MCMV retinitis in immunosuppressed BALB/c mice. J. Clin. Virol. 25:(suppl 2):2002;S137-S147.
59. Bigger J.E., et al. Murine cytomegalovirus infection causes apoptosis of uninfected retinal cell. Invest. Ophthalmol. Vis. Sci. 41:2000;2248-2254.
60. Chiou S.H., et al. Upregulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: a novel mechanism in cytomegalovirus-induced apoptosis in human retina. J. Immunol. 167:2001;4098-4103.
61. Buggage R.R., et al. Apoptosis in cytomegalovirus retinitis associated with AIDS. Curr. Eye Res. 21:2000;721-729.
62. Faden A.I. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr. Opin. Neurol. 15:2002;707-712.
63. Hoover D.R., et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophthalmol. 114:1996;821-827.
64. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:2001;372-377.
65. Crane I.J., et al. Regulation of granulocyte-macrophage colony-stimulating factor in human retinal pigment epithelial cells by IL-1β and IFN-γ Cell. Immunol. 209:2001;132-139.
66. Liebermann J., et al. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood. 98:2001;1667-1677.
67. Cohen O., et al. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159:1997;31-48.
68. Deeg H.J. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int. J. Hematol. 74:2001;26-32.
69. Krey, F. and Bräuer, H. (2002) CHIBRET Augenatlas. Eine Repetition für Ärzte mit Zeigetafeln für Patienten; zur Physiologie und Pathophysiologie des Auges. Chibret Pharmazeutische GMBH.